Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Hematology · Protein C Deficiency

Pregnancy and Family Planning

At a Glance

Protein C deficiency can increase clot risk during pregnancy and especially in the first six weeks after birth. Individual planning helps determine contraception, pregnancy-safe anticoagulation, delivery timing, breastfeeding options, and whether a partner should be tested.

Pregnancy and the postpartum period are times of significant change for your body’s clotting system. For someone with Protein C deficiency, these changes require careful planning. Because Protein C is one of your natural “brakes” on clotting, and pregnancy naturally increases your body’s “accelerants” to prevent excessive bleeding during birth, the balance shifts further toward a risk of clots [1][2].

Hormones and Contraception

If you have Protein C deficiency, the type of birth control you use matters significantly.

  • The Estrogen Risk: Combined oral contraceptives (the “Pill”), patches, and rings that contain estrogen are generally contraindicated or strongly discouraged in known thrombophilia, especially if you have had a prior VTE [3][4].
  • Safer Alternatives: Progestin-only options or non-hormonal options are usually preferred [5][6]. However, the risk profiles differ among the progestin-only pill, implant, levonorgestrel IUD, and depot injection; depot medroxyprogesterone may warrant more caution in people with thrombophilia. Individualized contraceptive counseling is essential to find the best method based on your clot history and bleeding risk.

Managing Pregnancy and Birth

While many women with Protein C deficiency have healthy pregnancies, the risk of a clot is elevated.

CRITICAL RULE: If you become pregnant while on warfarin or a DOAC, do NOT abruptly stop your anticoagulant. You need prompt contact with the prescribing clinician to plan a safe transition. Warfarin and DOACs are generally avoided during pregnancy due to fetal risks [7][8][9].

A Structured Pregnancy Timeline:

  1. Preconception: Review your history. If you have a prior VTE, your plan will be more aggressive than an asymptomatic carrier.
  2. Antepartum (During Pregnancy): If you need a blood thinner, you will likely be prescribed Low-Molecular-Weight Heparin (LMWH) injections [10][11]. Whether you need prophylactic (preventive) LMWH, therapeutic (full-dose) LMWH, or no medication depends on your prior VTE history and family history.
  3. Delivery & Neuraxial Anesthesia: Your obstetric and anesthesia teams will coordinate the exact timing of when to stop LMWH before labor so you can safely receive an epidural.
  4. Postpartum (The First Six Weeks): This is the highest-risk time for a clot. However, an asymptomatic heterozygous carrier without a personal VTE or relevant family history may not universally receive antepartum or postpartum prophylaxis under all guidelines. In contrast, someone with a previous VTE often does need postpartum prophylaxis [10][12]. If you choose to breastfeed, LMWH and warfarin are safe, but DOACs are typically avoided [13][14].

Genetics and Your Children

As a heterozygous carrier, you have a 50% probability of passing your pathogenic PROC variant to each of your children [15]. Many of these children will never have a clot, but they should be aware of their status [16]. Testing asymptomatic minors is a separate decision from testing a partner and is usually deferred unless the result will change care during childhood.

The Critical Risk (Biallelic): If both parents carry disease-causing pathogenic PROC variants, there is a 25% chance with each pregnancy that the child will inherit two mutated genes (homozygous or compound heterozygous). This causes severe congenital Protein C deficiency, which can present as Neonatal Purpura Fulminans (rapidly spreading, painful, purple skin lesions caused by widespread clotting shortly after birth) [17][18].

Because of this risk, if your partner is a blood relative or has a family history of early blood clots, it is highly recommended that they receive targeted testing before you conceive [19]. Genetic counseling is vital to explain these distinctions, as phenotype among biallelic variants can vary, and to help you plan [20].

Common questions in this guide

What should I do if I become pregnant while taking warfarin or a DOAC?
Contact the clinician who prescribed it promptly, and do not stop the medicine abruptly on your own. Warfarin and direct oral anticoagulants are generally avoided during pregnancy because of fetal risks; your clinician can plan a safe transition, often to low-molecular-weight heparin when anticoagulation is needed.
Will I need a blood thinner during pregnancy if I have protein C deficiency?
Not everyone with protein C deficiency needs medication during pregnancy. The decision between no medication, preventive-dose low-molecular-weight heparin, or full-dose treatment depends mainly on your history of venous blood clots and relevant family history. A previous clot often leads to preventive anticoagulation after delivery, although an asymptomatic carrier may not need it under every guideline.
Which birth control options are safest with protein C deficiency?
Estrogen-containing pills, patches, and rings are generally avoided or strongly discouraged, especially if you have had a previous venous blood clot. Progestin-only or non-hormonal methods are usually preferred, but their clot risks differ, so a clinician should help you choose.
How will my blood thinner be timed around labor and an epidural?
Your obstetric and anesthesia teams will coordinate when to stop low-molecular-weight heparin before labor or an epidural. The safe interval depends on the dose and your clinical plan, so do not change injection timing without instructions.
Can I breastfeed while taking anticoagulation after delivery?
Low-molecular-weight heparin and warfarin are considered compatible with breastfeeding. Direct oral anticoagulants are typically avoided while breastfeeding, so discuss the postpartum medicine plan with your prescribing and obstetric clinicians.
What are the chances my child will inherit protein C deficiency?
If you are a heterozygous carrier, each child has a 50% chance of inheriting your disease-causing PROC variant. A child who inherits one variant may never develop a clot, but knowing the status can help with future care. If both parents carry disease-causing variants, each pregnancy has a 25% chance of severe two-copy deficiency.
Should my partner have genetic testing before we try to conceive?
Testing is especially important to discuss if your partner is a blood relative or has a family history of early blood clots. Targeted testing and genetic counseling can clarify whether both parents carry a disease-causing PROC variant and help explain the risk to a child.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my Protein C level and my personal history (or lack thereof) of clots, do I need to start blood-thinning injections as soon as I get a positive pregnancy test?
  2. 2.What is the plan for my blood thinners when I go into labor? How many hours must pass after my last dose before I can safely have an epidural?
  3. 3.Is it safe for me to switch to warfarin after the baby is born if I plan to breastfeed?
  4. 4.If my partner has not been tested for Protein C deficiency, should that be done before we try to conceive?
  5. 5.Since I must avoid estrogen, what are the most effective progestin-only or non-hormonal birth control options for me?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Performance of Chromogenic Protein C (PC) Testing.

    Adams R, Coleman R, Stanton T

    Methods in molecular biology (Clifton, N.J.) 2023; (2663()):225-232 doi:10.1007/978-1-0716-3175-1_13.

    PMID: 37204713
  2. 2

    Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis.

    Croles FN, Nasserinejad K, Duvekot JJ, et al.

    BMJ (Clinical research ed.) 2017; (359()):j4452 doi:10.1136/bmj.j4452.

    PMID: 29074563
  3. 3

    American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.

    Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al.

    Blood advances 2023; (7(22)):7101-7138 doi:10.1182/bloodadvances.2023010177.

    PMID: 37195076
  4. 4

    Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis.

    van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K

    Journal of thrombosis and haemostasis : JTH 2016; (14(7)):1393-403 doi:10.1111/jth.13349.

    PMID: 27121914
  5. 5

    Cost-effective screening strategy to prevent venous thromboembolism in combined oral contraceptive users.

    Douxfils J

    Frontiers in endocrinology 2025; (16()):1559162 doi:10.3389/fendo.2025.1559162.

    PMID: 40575268
  6. 6

    Sex hormone-binding globulin and thrombin generation in women using hormonal contraception.

    Hugon-Rodin J, Alhenc-Gelas M, Hemker HC, et al.

    Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2017; (22(1)):81-85 doi:10.1080/1354750X.2016.1204010.

    PMID: 27323874
  7. 7

    First Trimester Anticoagulant Exposure and Adverse Pregnancy Outcomes in Women with Preconception Venous Thromboembolism: A Nationwide Cohort Study.

    Søgaard M, Skjøth F, Nielsen PB, et al.

    The American journal of medicine 2022; (135(4)):493-502.e5 doi:10.1016/j.amjmed.2021.10.023.

    PMID: 34798098
  8. 8

    How Do We Treat Pregnancy-Related Venous Thromboembolism?

    Linnemann B, Seelbach-Goebel B, Heimerl S, Hart C

    Hamostaseologie 2020; (40(1)):54-63 doi:10.1055/s-0039-1700501.

    PMID: 31683346
  9. 9

    Pulmonary Embolism in Pregnancy.

    Bates SM

    Seminars in respiratory and critical care medicine 2021; (42(2)):284-298 doi:10.1055/s-0041-1722867.

    PMID: 33548928
  10. 10

    How I treat venous thromboembolism in pregnancy.

    Middeldorp S, Ganzevoort W

    Blood 2020; (136(19)):2133-2142 doi:10.1182/blood.2019000963.

    PMID: 32797192
  11. 11

    Management of Venous Thromboembolism in Pregnancy.

    Fogerty AE

    Current treatment options in cardiovascular medicine 2018; (20(8)):69 doi:10.1007/s11936-018-0658-3.

    PMID: 30039233
  12. 12

    Contemporary best practice in the management of pulmonary embolism during pregnancy.

    Wiegers HMG, Middeldorp S

    Therapeutic advances in respiratory disease 2020; (14()):1753466620914222 doi:10.1177/1753466620914222.

    PMID: 32425105
  13. 13

    Prophylaxis and Therapy of Venous Thrombotic Events (VTE) in Pregnancy and the Postpartum Period.

    Sucker C

    Geburtshilfe und Frauenheilkunde 2020; (80(1)):48-59 doi:10.1055/a-1030-4546.

    PMID: 31949319
  14. 14

    Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation.

    DeLoughery E, Bannow BS

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):467-473 doi:10.1182/hematology.2022000401.

    PMID: 36485151
  15. 15

    Protein C Deficiency Caused by a Novel Mutation in the PROC Gene in an Infant with Delayed Onset Purpura Fulminans.

    Al Harbi MS, El-Hattab AW

    Case reports in dermatological medicine 2017; (2017()):8915608 doi:10.1155/2017/8915608.

    PMID: 29082047
  16. 16

    Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH.

    Cooper PC, Pavlova A, Moore GW, et al.

    Journal of thrombosis and haemostasis : JTH 2020; (18(2)):271-277 doi:10.1111/jth.14667.

    PMID: 31999059
  17. 17

    Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH.

    Minford A, Brandão LR, Othman M, et al.

    Journal of thrombosis and haemostasis : JTH 2022; (20(7)):1735-1743 doi:10.1111/jth.15732.

    PMID: 35570324
  18. 18

    Clinical and genetic features of Chinese pediatric patients with severe congenital protein C deficiency who first presented with purpura fulminans: A case series study and literature review.

    Tang X, Zhang Z, Yang H, et al.

    Thrombosis research 2022; (210()):70-77 doi:10.1016/j.thromres.2021.12.026.

    PMID: 35026611
  19. 19

    Molecular characterization of novel splice site mutation causing protein C deficiency.

    Al-Hamed MH, AlBatniji F, AlDakheel GA, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2016; (27(5)):585-8 doi:10.1097/MBC.0000000000000490.

    PMID: 26656900
  20. 20

    Prenatal genetic testing for familial severe congenital protein C deficiency.

    Tairaku S, Taniguchi-Ikeda M, Okazaki Y, et al.

    Human genome variation 2015; (2()):15017 doi:10.1038/hgv.2015.17.

    PMID: 27081530

This page is for informational purposes only and does not constitute medical advice. Decisions about pregnancy, anticoagulation, contraception, and genetic testing should be made with your obstetric, hematology, and genetics clinicians.

Get notified when new evidence is published on thrombophilia due to protein C deficiency, autosomal dominant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.